Ascendis Pharma A/S - American Depositary Shares (ASND)

Ascendis Pharma (NASDAQ: ASND) has outperformed the market over the past 10 years by 13.64% on an annualized basis producing an average annual return of 26.77%. Currently, Ascendis Pharma has a market capitalization of $11.48 billion.

BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study.

Ascendis Pharma (ASND) excels in both technical & fundamental momentum, meeting Minervini's Trend Template criteria for high-growth stocks poised for potential outperformance.

A fundamental and technical analysis of (NASDAQ:ASND): Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) suited for high growth investing?